ALK-Abelló Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de ALK-Abelló de 19.5% y 10.3% por año respectivamente. Se prevé que el BPA crezca en un 19% al año. Se espera que la rentabilidad financiera sea de 19.6% en 3 años.

Información clave

27.5%

Tasa de crecimiento de los beneficios

17.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	15.4%
Tasa de crecimiento de los ingresos	10.1%
Rentabilidad financiera futura	19.9%
Cobertura de analistas	Low
Última actualización	23 Sep 2024

Actualizaciones recientes sobre el crecimiento futuro

Analysts Have Made A Financial Statement On ALK-Abelló A/S' (CPH:ALK B) Second-Quarter Report

Aug 25

ALK-Abelló A/S (CPH:ALK B) Released Earnings Last Week And Analysts Lifted Their Price Target To kr.143

May 05

Recent updates

Analysts Have Made A Financial Statement On ALK-Abelló A/S' (CPH:ALK B) Second-Quarter Report

Aug 25

ALK-Abelló A/S (CPH:ALK B) Released Earnings Last Week And Analysts Lifted Their Price Target To kr.143

May 05

ALK-Abelló A/S' (CPH:ALK B) Share Price Matching Investor Opinion

Apr 27

ALK-Abelló A/S (CPH:ALK B) Shares Could Be 29% Below Their Intrinsic Value Estimate

Mar 06

ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

Jan 19

With ALK-Abelló A/S (CPH:ALK B) It Looks Like You'll Get What You Pay For

Jan 01

Is ALK-Abelló (CPH:ALK B) A Risky Investment?

Sep 09

ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

Jun 11

Is ALK-Abelló A/S (CPH:ALK B) Trading At A 26% Discount?

May 24

ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

Mar 12

ALK-Abelló A/S (CPH:ALK B) Shares Could Be 26% Below Their Intrinsic Value Estimate

Feb 17

Investors Interested In ALK-Abelló A/S' (CPH:ALK B) Earnings

Jan 30

ALK-Abelló (CPH:ALK B) Seems To Use Debt Rather Sparingly

Dec 05

Is ALK-Abelló A/S (CPH:ALK B) Trading At A 32% Discount?

Nov 11

Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?

Sep 01

Calculating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)

Aug 05

We Think ALK-Abelló (CPH:ALK B) Can Manage Its Debt With Ease

May 12

Estimating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)

Apr 21

Is Now The Time To Put ALK-Abelló (CPH:ALK B) On Your Watchlist?

Mar 31

Previsiones de crecimiento de beneficios e ingresos

CPSE:ALK B - Estimaciones futuras de los analistas y datos financieros pasados (DKK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	6,886	1,387	1,057	1,519	4
12/31/2025	6,224	1,222	799	1,295	5
12/31/2024	5,568	878	385	831	5
6/30/2024	5,180	690	724	1,046	N/A
3/31/2024	4,941	555	449	796	N/A
12/31/2023	4,824	486	288	667	N/A
9/30/2023	4,728	424	17	426	N/A
6/30/2023	4,680	359	-76	343	N/A
3/31/2023	4,590	335	90	479	N/A
12/31/2022	4,511	335	63	416	N/A
9/30/2022	4,361	333	149	489	N/A
6/30/2022	4,227	318	163	493	N/A
3/31/2022	4,050	255	152	432	N/A
12/31/2021	3,916	219	205	468	N/A
9/30/2021	3,808	112	273	505	N/A
6/30/2021	3,652	55	158	358	N/A
3/31/2021	3,556	66	147	358	N/A
12/31/2020	3,491	25	79	301	N/A
9/30/2020	3,383	43	87	298	N/A
6/30/2020	3,350	49	149	353	N/A
3/31/2020	3,363	-9	-14	172	N/A
12/31/2019	3,274	-50	-35	132	N/A
9/30/2019	3,178	-183	-104	59	N/A
6/30/2019	3,100	-200	-211	-54	N/A
3/31/2019	3,030	-149	-205	-27	N/A
12/31/2018	2,915	-170	-273	-95	N/A
9/30/2018	2,891	-183	-394	-223	N/A
6/30/2018	2,897	-152	-409	-214	N/A
3/31/2018	2,873	-136	N/A	-386	N/A
12/31/2017	2,910	-158	N/A	-387	N/A
9/30/2017	2,901	37	N/A	-278	N/A
6/30/2017	2,864	76	N/A	-146	N/A
3/31/2017	2,946	149	N/A	206	N/A
12/31/2016	3,005	270	N/A	405	N/A
9/30/2016	2,938	373	N/A	492	N/A
6/30/2016	2,975	396	N/A	458	N/A
3/31/2016	2,767	378	N/A	312	N/A
12/31/2015	2,569	344	N/A	183	N/A
9/30/2015	2,494	221	N/A	153	N/A
6/30/2015	2,349	185	N/A	136	N/A
3/31/2015	2,399	162	N/A	258	N/A
12/31/2014	2,433	181	N/A	320	N/A
9/30/2014	2,414	205	N/A	307	N/A
6/30/2014	2,401	188	N/A	330	N/A
3/31/2014	2,318	127	N/A	157	N/A
12/31/2013	2,244	61	N/A	146	N/A
9/30/2013	2,266	6	N/A	98	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (19.5% al año) de ALK B es superior a la tasa de ahorro (1%).

Beneficios vs. Mercado: Se prevé que los beneficios (19.5% al año) de ALK B crezcan más rápidamente que el mercado Danish (14.2% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de ALK B crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (10.3% al año) de ALK B crezcan más despacio que el mercado de Danish (10.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 10.3% al año) de ALK B crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de ALK B sea baja dentro de 3 años (19.6%).

ALK-Abelló Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Analysts Have Made A Financial Statement On ALK-Abelló A/S' (CPH:ALK B) Second-Quarter Report

ALK-Abelló A/S Revises Earnings Guidance for the 2024

ALK-Abelló A/S (CPH:ALK B) Released Earnings Last Week And Analysts Lifted Their Price Target To kr.143

Price target increased by 15% to kr.143

ALK-Abelló A/S Updates Revenue Guidance for the Year 2024

Price target increased by 7.8% to kr.121

Recent updates

Insider exercised options to buy kr.6.3m worth of stock.

Analysts Have Made A Financial Statement On ALK-Abelló A/S' (CPH:ALK B) Second-Quarter Report

Second quarter 2024 earnings released: EPS: kr.0.90 (vs kr.0.30 in 2Q 2023)

ALK-Abelló A/S Revises Earnings Guidance for the 2024

What You Can Learn From ALK-Abelló A/S' (CPH:ALK B) P/E

Now 22% undervalued

New minor risk - Share price stability

Is ALK-Abelló (CPH:ALK B) Using Too Much Debt?

A Look At The Intrinsic Value Of ALK-Abelló A/S (CPH:ALK B)

ALK Presents Positive Phase 3 Paediatric Trial Data Offering New Hope for Children with Respiratory Allergy

Alk's European Registration Application for Itulazax for Pneumiatric Indication Accepted for Review

Now 20% undervalued

Investor sentiment improves as stock rises 17%

ALK-Abelló A/S (CPH:ALK B) Released Earnings Last Week And Analysts Lifted Their Price Target To kr.143

Price target increased by 15% to kr.143

First quarter 2024 earnings released

ALK-Abelló A/S Updates Revenue Guidance for the Year 2024

ALK-Abelló A/S' (CPH:ALK B) Share Price Matching Investor Opinion

ALK-Abelló A/S (CPH:ALK B) Shares Could Be 29% Below Their Intrinsic Value Estimate

Insider recently sold kr.9.0m worth of stock

Price target increased by 7.8% to kr.121

Full year 2023 earnings released

Alk-Abelló A/S Provides Revenue Guidance for the Year of 2024

Alk's European Registration Application for House Dust Mite Slit-Tablet in Young Children Accepts for Review

ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

ALK-Abelló A/S Completes First Part of Phase 1 Trial with Peanut Slit-Tablet

With ALK-Abelló A/S (CPH:ALK B) It Looks Like You'll Get What You Pay For

ALK-Abelló A/S to Report Q2, 2024 Results on Aug 23, 2024

Price target decreased by 7.3% to kr.109

Third quarter 2023 earnings released: EPS: kr.0.50 (vs kr.0.20 in 3Q 2022)

ALK-Abelló A/S to Report Fiscal Year 2023 Results on Feb 08, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 23%

Alk-Abelló A/S Provides Earnings Guidance for the Year 2023

ALK Announces Top-Line Results from A Phase 3 Pneumiatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of Tree-Pollen-Induced Allergy Immunotherapy Tablet

Is ALK-Abelló (CPH:ALK B) A Risky Investment?

ALK-Abelló A/S Narrows Revenue Guidance for the Full Year 2023

Price target decreased by 9.2% to kr.116

Investor sentiment deteriorates as stock falls 15%

New major risk - Share price stability

Alk-Abelló A/S Announces Executive Changes

ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

Alk Announces Top-Line Results from A Phase 3 Paediatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis

Is ALK-Abelló A/S (CPH:ALK B) Trading At A 26% Discount?

ALK-Abelló A/S Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings released

Price target decreased by 8.5% to kr.129

Investor sentiment deteriorates as stock falls 22%

ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

ALK-Abelló A/S (CPH:ALK B) Shares Could Be 26% Below Their Intrinsic Value Estimate

ALK Announces Management Changes

Full year 2022 earnings: Revenues exceed analyst expectations

ALK-Abelló A/S Provides Revenue Guidance for the Full Year 2023

Investors Interested In ALK-Abelló A/S' (CPH:ALK B) Earnings

U.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents

ALK-Abelló A/S Announces Executive Changes

ALK-Abelló A/S, Annual General Meeting, Mar 23, 2023

ALK-Abelló (CPH:ALK B) Seems To Use Debt Rather Sparingly

ALK Announces Resignation of Søren Jelert as CFO, Effective May 31, 2023

Less than half of directors are independent

Third quarter 2022 earnings released

Is ALK-Abelló A/S (CPH:ALK B) Trading At A 32% Discount?

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022

Price target decreased to kr.161

Investor sentiment deteriorated over the past week

Now 21% undervalued after recent price drop

Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?

Second quarter 2022 earnings: Revenues exceed analyst expectations

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022